摘要
原发免疫性血小板减少症是一种以血小板生成障碍和血小板破坏增加为主要特征的自身免疫性出血性疾病,其发病机制尚不明确。随着研究的深入,越来越多的发病机制的可能性已经被提出,目前调节性T细胞和辅助性T细胞的免疫调节作用在体液免疫和细胞免疫介导的血小板过度破坏和巨核细胞数量及质量异常导致的血小板生成不足中发挥关键作用的理论被广泛提出。因为对于原发免疫性血小板减少症患者做出早期诊断的困难性以及部分患者疾病的难治性,明确其发病机制尤为重要,有助于对患者情况进行及时了解,做出正确的医疗干预。本研究归纳了T淋巴细胞在原发免疫性血小板减少症的主要研究进展。
Primary immune thrombocytopenia is an autoimmune hemorrhagic disease mainly characterized by impaired platelet production and increased platelet destruction, and the pathogenesis has not yet been clarified. With the deepening of research, more and more possibilities of pathogenesis have been proposed.At present, the theory that the immune regulation by regulatory T cells and T helper cells plays a key role in the excessive platelet destruction mediated by humoral and cellular immunity and the insufficient platelet production caused by the abnormal number and quality of megakaryocytes has been widely proposed. Due to the difficulty in making early diagnosis for patients with primary immune thrombocytopenia and the refractoriness in some patients’ diseases, it is particularly important to clarify the pathogenesis, which helps to understand the patient’s situation in time and make correct medical intervention. This review summarizes the main progress of the studies on T lymphocytes in primary immune thrombocytopenia.
作者
陈昊
袁野
任一文
周攀
CHEN Hao;YUAN Ye;REN Yiwen;ZHOU Pan(School of Laboratory Medicine,Southwest Medical University,Sichuan,Luzhou 646000,China;School of Clinical Medicine,Southwest Medical University,Sichuan,Luzhou 646000,China;Department of Laboratory Medicine,the Affiliated Hospital of Southwest Medical University,Sichuan,Luzhou 646000,China)
出处
《中国医药科学》
2022年第23期47-49,58,共4页
China Medicine And Pharmacy
基金
四川省省级大学生创新创业训练计划项目(S20201062173)。
